Strander H
Research Laboratory of Radiumhemmet, Karolinska Hospital, Stockholm, Sweden.
Med Oncol. 2001;18(1):3-14. doi: 10.1385/mo:18:1:3.
Since their introduction to the clinic some 30 yr ago, interferons (IFNs) have become standard therapy for a range of disorders, including malignant and benign tumors as well as various viral diseases. Although IFNs will induce remissions in some patients with cancer, they are of no benefit or, at best, lead only to minor improvements in the great majority of patients with malignant disease. One of the great challenges of IFN research is to understand the multiple ways by which IFNs influence the behavior of tumor cells and to identify the factors that underlie the resistance of some tumors to IFNs. This review is written with a focus on two anticellular effects of IFN, inhibition of proliferation and induction of apoptosis, possible mechanisms underlying the antitumor action of IFN. In addition, possible reasons for IFN tumor cell resistance are also discussed.
大约30年前干扰素（IFNs）引入临床以来，已成为一系列疾病的标准治疗方法，包括恶性和良性肿瘤以及各种病毒性疾病。尽管干扰素能使一些癌症患者病情缓解，但对绝大多数恶性疾病患者并无益处，或至多只能带来轻微改善。干扰素研究的一大挑战是了解干扰素影响肿瘤细胞行为的多种方式，并确定某些肿瘤对干扰素耐药的潜在因素。本综述重点阐述干扰素的两种抗细胞效应，即抑制增殖和诱导凋亡，这可能是干扰素抗肿瘤作用的潜在机制。此外，还讨论了干扰素肿瘤细胞耐药的可能原因。
